The leap from animal to human organs is being cheered as a potential lifesaver, with the first clinical trial of gene-edited pig kidneys underway at NYU Langone Health. The bold plan could eventually ease waiting lists that claim thousands of lives each year—more than 100,000 people on US transplant lists, and over 10,000 on similar lists across eight European countries.
The FDA permitted these studies after prior compassionate-use experiments, even as earlier pig-kidney transplants showed mixed longevity. The newest trial, led by NYU’s Dr. Robert Montgomery, tests pig kidneys engineered with 10 gene edits to curb early rejection and improve human compatibility. If results are promising, the study could expand from six participants to as many as 50, with more transplant centers joining.
A second US company, eGenesis, plans to start its own trial in the coming months, signaling growing confidence in xenotransplantation—even as patient privacy remains protected and timelines stay opaque. Yet the horizon is far from clear. A kidney lasting 271 days in Mass General Hospital’s patient ended when the pig organ declined, and others have lasted far shorter—and the long-term safety, including cross-species infections or unforeseen immune responses, remains a live concern.
In parallel, critics argue the field is still in its infancy, demanding rigorous, multi-center verification before we declare this a new standard of care. The broader context matters: organ shortages are acute, and the potential payoff is substantial—but so are the unknowns that could reframe or slow progress.
